AACR centennial series: The biology of cancer metastasis: Historical perspective

Cancer Research

Volumn 70, Issue 14, 2010, Pages 5649-5669

  Talmadge, James E ^a   Fidler, Isaiah J ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR;

CANCER RESEARCH; CANCER STEM CELL; CANCER SURVIVAL; CELL HETEROGENEITY; CLONAL VARIATION; EPITHELIUM CELL; GENE EXPRESSION; HISTORY OF MEDICINE; HUMAN; LYMPH NODE METASTASIS; MACROPHAGE; MESENCHYME CELL; METASTASIS; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY; TUMOR VASCULARIZATION;

HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 77955015464     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1040     Document Type: Review

References (236)

1. Recamier JC. Recherches sur le traitement du cancer sur la compression methodique simple ou combinee et sur l'histoire generale de la meme maladie. 2nd ed. 1829.
2. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
3. Dorland WA. Dorland's illustrated medical dictionary. 24th ed. Philadelphia (PA): Saunders Co.; 1965.
4. Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle 2009;8:505-6.
5. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
6. Weigelt B, Glas AM, Wessels LF, et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003;100:15901-5.
7. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33: 49-54.
8. Suzuki M, Tarin D. Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Mol Oncol 2007;1:172-80.
9. Urquidi V, Sloan D, Kawai K, et al. Contrasting expression of thrombospondin- 1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 2002;8:61-74.
10. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893-5.
11. Kripke ML, Gruys E, Fidler IJ. Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res 1978;38:2962-7.
12. Nicolson GL, Brunson KW, Fidler IJ. Specificity of arrest, survival, and growth of selected metastatic variant cell lines. Cancer Res 1978;38:4105-11.
13. Poste G, Doll J, Fidler IJ. Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci U S A 1981;78: 6226-30.
14. Kozlowski JM, Hart IR, Fidler IJ, Hanna N. A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst 1984;72:913-7.
15. Montel V, Huang TY, Mose E, Pestonjamasp K, Tarin D. Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Pathol 2005;166: 1565-79.
16. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980;283:139-46.
17. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;133:571-3.
18. Virchow R. Cellular pathologie, 1858. Nutr Rev 1989;47:23-5.
19. Ewing J. Neoplastic diseases: a treatise on tumors. 3rd ed. Philadelphia (PA): WB Saunders; 1928.
20. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980;40:2281-7.
21. Fidler IJ, Talmadge JE. Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res 1986;46:5167-71.
22. 125I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 1970;45:773-82.
23. Talmadge JE, Fidler IJ. Cancer metastasis is selective or random depending on the parent tumor population. Nature 1978;27:593-4.
24. Raz A, Hanna N, Fidler IJ. In vivo isolation of a metastatic tumor cell variant involving selective and nonadaptive processes. J Natl Cancer Inst 1981;66:183-9.
25. Talmadge JE, Fidler IJ. Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. J Natl Cancer Inst 1982;69:975-80.
26. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978;38:2651-60.
27. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 2007; 28:297-321.
28. Price JE, Aukerman SL, Fidler IJ. Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res 1986;46:5172-8.
29. Willis RA. The spread of tumors in the human body. London: Butterworths and Company; 1952. pp. 1-447.
30. Fidler IJ, Gersten DM, Hart IR. The biology of cancer invasion and metastasis. Adv Cancer Res 1978;28:149-250.
31. Nicolson GL. Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 1988;948:175-224.
32. Naito S, Giavazzi R, Fidler IJ. Correlation between the in vitro interaction of tumor cells with an organ environment and metastatic behavior in vivo. Invasion Metastasis 1987;7:16-29.
33. Price JE, Naito S, Fidler IJ. Growth in an organ microenvironment as a selective process in metastasis. Clin Exp Metastasis 1988;6: 91-102.
34. Sugarbaker EV. Cancer metastasis: a product of tumor-host interactions. Curr Probl Cancer 1979;3:1-59.
35. Weiss L. Principles of metastasis. Orlando (FL): Academic Press; 1985.
36. Fidler IJ, Kripke ML. Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet 2003;34:23.
37. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2:563-72.
38. Weiss L. Metastatic inefficiency: causes and consequences. Cancer Rev 1986;3:1-24.
39. Chen LL, Blumm N, Christakis NA, Barabasi AL, Deisboeck TS. Cancer metastasis networks and the prediction of progression patterns. Br J Cancer 2009;101:749-58.
40. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975;35:218-24.
41. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008;359:2814-23.
42. Waghorne C, Thomas M, Lagarde A, Kerbel RS, Breitman ML. Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res 1988;48: 6109-14.
43. Wang K, Li J, Li S, Bolund L, Wiuf C. Estimation of tumor heterogeneity using CGH array data. BMC Bioinformatics 2009;10:12.
44. Kuukasjarvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997;57:1597-604.
45. Bissig H, Richter J, Desper R, et al. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am J Pathol 1999;155: 267-74.
46. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 1975;35:512-6.
47. Tarin D, Price JE, Kettlewell MG, et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984;44:3584-92.
48. Kasimir-Bauer S. Circulating tumor cells as markers for cancer risk assessment and treatment monitoring. Mol Diagn Ther 2009;13: 209-15.
49. Arnerlöv C, Emdin SO, Lundgren B, et al. Breast carcinoma growth rate described by mammographic doubling time and S-phase fraction. Correlations to clinical and histopathologic factors in a screened population. Cancer 1992;70:1928-34.
50. Shackney SE, McCormack GW, Cuchural GJ, Jr. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann Intern Med 1978;89:107-21.
51. von Fournier D, Weber E, Hoeffken W, et al. Growth rate of 147 mammary carcinomas. Cancer 1980;45:2198-207.
52. Peer PG, van Dijck JA, Hendriks JH, Holland R, Verbeek AL. Age-dependent growth rate of primary breast cancer. Cancer 1993;71:3547-51.
53. Fidler IJ, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Probl Surg 1987;24:129-209.
54. Engel J, Eckel R, Kerr J, et al. The process of metastasisation for breast cancer. Eur J Cancer 2003;39:1794-806.
55. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105:4283-8.
56. Robinson SN, Chavez JM, Blonder JM, et al. Hematopoietic progenitor cell mobilization in mice by sustained delivery of granulocyte colony-stimulating factor. J Interferon Cytokine Res 2005;25: 490-500.
57. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70.
58. Staab HJ, Anderer FA, Hornung A, Stumpf E, Fischer R. Doubling time of circulating cea and its relation to survival of patients with recurrent colorectal cancer. Br J Cancer 1982;46:773-81.
59. Price JE, Tarin D, Fidler IJ. Influence of organ microenvironment on pigmentation of a metastatic murine melanoma. Cancer Res 1988; 48:2258-64.
60. Schackert G, Fidler IJ. Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res 1988;48:3478-84.
61. Nicolson GL. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 1988;7:143-88.
62. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002;70:498-505.
63. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet 1998;14:272-6.
64. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990;50:6130-8.
65. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-6.
66. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003;95:458-70.
67. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002;12:89-96.
68. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101.
69. Fuchs E. In: Braumueller W, editor. Metastasenbildung. Wien: Sarcom des Uvealtractus; 1882, p. 197-206.
70. Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 2004;32:397-402.
71. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
72. Huang EH, Singh B, Cristofanilli M, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 2009;155:231-6.
73. Zeelenberg IS, Ruuls-Van SL, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;63:3833-9.
74. Andrea S, Emanuela M, Chiara C, et al. CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther 2009;8: 1608-14.
75. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3: 537-49.
76. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
77. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170:793-804.
78. Sone S, Fidler IJ. Activation of rat alveolar macrophages to the tumoricidal state in the presence of progressively growing pulmonary metastases. Cancer Res 1981;41:2401-6.
79. Eccles SA, Alexander P. Macrophage content of tumours in relation to metastatic spread and host immune reaction. Nature 1974;250: 667-9.
80. Gauci CL, Alexander P. The macrophage content of some human tumors. Cancer Lett 1975;1:29-32.
81. Evans R, Lawler EM. Macrophage content and immunogenicity of C57BL/6J and BALB/cByJ methylcholanthrene-induced sarcomas. Int J Cancer 1980;26:831-5.
82. Key M, Talmadge JE, Fidler IJ. Lack of correlation between the progressive growth of spontaneous metastases and their content of infiltrating macrophages. J Reticuloendothel Soc 1982; 32:387-96.
83. Kripke ML, Fisher MS. Immunologic parameters of ultraviolet carcinogenesis. J Natl Cancer Inst 1976;57:211-5.
84. Pross HF, Kerbel RS. An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passaged chemically induced murine sarcomas. J Natl Cancer Inst 1976;57:1157-67.
85. Watanabe T, Dave B, Heimann DG, et al. GM-CSF-mobilized peripheral blood CD34+ cells differ from steady- state bone marrow CD34+ cells in adhesion molecule expression. Bone Marrow Transplant 1997;19:1175-81.
86. Ross J, Auger M. The biology of the macrophage. In: Burke B, Lewis C, editors. The macrophage. 2nd ed. Oxford: University Press; 2002.
87. Mantovani A. Effects on in vitro tumor growth of murine macrophages isolated from sarcoma lines differing in immunogenicity and metastasizing capacity. Int J Cancer 1978;22:741-6.
88. Steele RJ, Eremin O, Brown M, Hawkins RA. A high macrophage content in human breast cancer is not associated with favourable prognostic factors. Br J Surg 1984;71:456-8.
89. Sun XF, Zhang H. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer 2006;5: 43-63.
90. Fidler IJ, Schackert G, Zhang RD, Radinsky R, Fujimaki T. The biology of melanoma brain metastasis. Cancer Metastasis Rev 1999; 18:387-400.
91. Alexander P, Eccles SA, Gauci CL. The significance of macrophages in human and experimental tumors. Ann N Y Acad Sci 1976;276:124-33.
92. Donkor MK, Lahue E, Hoke TA, et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol 2009;9:937-48.
93. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-40.
94. Hagemann T, Robinson SC, Schulz M, et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-α dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004;25:1543-9.
95. Hamada I, Kato M, Yamasaki T, et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res 2002;22:4281-4.
96. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 2005;167:627-35.
97. Bronte V, Wang M, Overwijk WW, et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 1998;161:5313-20.
98. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005;174:4880-91.
99. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006;66:9299-307.
100. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
101. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6:1755-66.
102. Strober S. Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships. Annu Rev Immunol 1984;2:219-37.
103. Badger AM, King AG, Talmadge JE, et al. Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SK&F 105685. J Autoimmun 1990;3:485-500.
104. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/ Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000;96:3838-46.
105. Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol 1999;21:241-52.
106. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003;22:3188-92.
107. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001;23:263-72.
108. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66.
109. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000;5[Suppl 1]:11-5.
110. Toi M, Kondo S, Suzuki H, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996;77: 1101-6.
111. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
112. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 1998;78:1573-7.
113. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-70.
114. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82.
115. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
116. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973;242:148-9.
117. Nicolson GL, Dulski KM. Organ specificity of metastatic tumor colonization is related to organ-selective growth properties of malignant cells. Int J Cancer 1986;38:289-94.
118. Fidler IJ. General considerations for studies of experimental cancer metastasis. In: Busch H, editor. Methods of cancer research, Vol. XV. New York: New Academic Press; 1978, p 399-439.
119. Brunson KW, Nicolson GL. Selection and biologic properties of malignant variants of a murine lymphosarcoma. J Natl Cancer Inst 1978;61:1499-503.
120. Fidler IJ, Gersten DM, Budmen MB. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte- mediated cytotoxicity. Cancer Res 1976;36:3160-5.
121. Briles EB, Kornfeld S. Isolation and metastatic properties of detachment variants of B16 melanoma cells. J Natl Cancer Inst 1978;60: 1217-22.
122. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 1979;97:587-600.
123. Poste G, Doll J, Hart IR, Fidler IJ. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 1980;40:1636-44.
124. Kerbel RS. Immunologic studies of membrane mutants of a highly metastatic murine tumor. Am J Pathol 1979;97:609-22.
125. Hanna N. Role of natural killer cells in control of cancer metastasis. Cancer Metastasis Rev 1982;1:45-64.
126. Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943;28:491-511.
127. Kripke ML. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979;63: 541-8.
128. Fidler IJ, Kripke ML. Metastatic heterogeneity of cells from the K- 1735 melanoma. In: Grundmann E, editor. Metastatic tumor growth. Stuttgart: Gustav Fischer Verlag; 1980, p. 71-81.
129. Fidler IJ, Gruys E, Cifone MA, Barnes Z, Bucana C. Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J Natl Cancer Inst 1981;67:947-56.
130. Fidler IJ, Gersten DM, Kripke ML. Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res 1979;39:3816-21.
131. Fidler IJ, Kripke ML. Tumor cell antigenicity, host immunity and cancer metastasis. Cancer Immunol Immunother 1980;7:201-5.
132. Aukerman SL, Price JE, Fidler IJ. Different deficiencies in the prevention of tumorigenic-low-metastatic murine K-1735b melanoma cells from producing metastases. J Natl Cancer Inst 1986;77: 915-24.
133. Heppner GH. Tumor heterogeneity. Cancer Res 1984;44:2259-65.
134. Nicolson GL, Custead SE. Tumor metastasis is not due to adaptation of cells to a new organ environment. Science 1982;215: 176-8.
135. Poste G. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rep 1986;70:183-99.
136. Nakamura T, Kuwai T, Kitadai Y, et al. Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res 2007;67: 7597-604.
137. Bachtiary B, Boutros PC, Pintilie M, et al. Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res 2006;12:5632-40.
138. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
139. Pettaway CA, Pathak S, Greene G, et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2: 1627-36.
140. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
141. Nowell PC. Chromosomal and molecular clues to tumor progression. Semin Oncol 1989;16:116-27.
142. Cifone MA, Fidler IJ. Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci U S A 1981;78:6949-52.
143. Hill RP, Chambers AF, Ling V, Harris JF. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. Science 1984;224:998-1001.
144. Masramon L, Vendrell E, Tarafa G, et al. Genetic instability and divergence of clonal populations in colon cancer cells in vitro. J Cell Sci 2006;119:1477-82.
145. Jones TD, Carr MD, Eble JN, et al. Clonal origin of lymph node metastases in bladder carcinoma. Cancer 2005;104:1901-10.
146. Welch DR, Tomasovic SP. Implications of tumor progression on clinical oncology. Clin Exp Metastasis 1985;3:151-88.
147. Poste G, Greig R. On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion Metastasis 1982;2:137-76.
148. Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastases. Science 1982;217:361-3.
149. Talmadge JE, Zbar B. Clonality of pulmonary metastases from the bladder 6 subline of the B16 melanoma studied by southern hybridization. J Natl Cancer Inst 1987;78:315-20.
150. Poste G, Tzeng J, Doll J, et al. Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc Natl Acad Sci U S A 1982;79:6574-8.
151. Ootsuyama A, Tanaka K, Tanooka H. Evidence by cellular mosaicism for monoclonal metastasis of spontaneous mouse mammary tumors. J Natl Cancer Inst 1987;78:1223-7.
152. Talmadge C, Tanio Y, Meeker A, Talmadge J, Zbar B. Tumor cells transfected with the neomycin resistance gene (neo) contain unique genetic markers useful for identification of tumor recurrence and metastasis. Invasion Metastasis 1987;7:197-207.
153. Korczak B, Robson IB, Lamarche C, Bernstein A, Kerbel RS. Genetic tagging of tumor cells with retrovirus vectors: clonal analysis of tumor growth and metastasis in vivo. Mol Cell Biol 1988;8:3143-9.
154. Talmadge JE, Benedict K, Madsen J, Fidler IJ. Development of biological diversity and susceptibility to chemotherapy in murine cancer metastases. Cancer Res 1984;44:3801-5.
155. Wolman SR, McMorrow LE, Fidler IJ, Talmadge JE. Development and progression of karyotypic variability in melanoma K1735 following X-irradiation. Cancer Res 1985;45:1839-44.
156. Kaplan RN, Rafii S, Lyden D. Preparing the "soil":the premetastatic niche. Cancer Res 2006;66:11089-93.
157. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
158. Gao D, Nolan DJ, Mellick AS, et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008; 319:195-8.
159. Talmadge JE, Key M, Fidler IJ. Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol 1981;126:2245-8.
160. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28:299-307.
161. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 2008;27:11-8.
162. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002;19:247-58.
163. Chen Q, Wang WC, Evans SS. Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 2003;52:670-9.
164. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9.
165. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717-27.
166. Malmberg KJ. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 2004;53:879-92.
167. Batlle E, Sancho E, Franci C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000;2:84-9.
168. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
169. Hartwell KA, Muir B, Reinhardt F, et al. The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc Natl Acad Sci U S A 2006;103:18969-74.
170. Spaderna S, Schmalhofer O, Wahlbuhl M, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008;68:537-44.
171. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
172. Duband JL, Monier F, Delannet M, Newgreen D. Epithelium-mesenchyme transition during neural crest development. Acta Anat (Basel) 1995;154:63-78.
173. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast- derived modulator of epithelial cell mobility. Nature 1987;327: 239-42.
174. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995;154:8-20.
175. Greenburg G, Hay ED. Cytodifferentiation and tissue phenotype change during transformation of embryonic lens epithelium to mesenchyme-like cells in vitro. Dev Biol 1986;115:363-79.
176. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42.
177. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005;65:5991-5.
178. Delinassios JG, Kottaridis SD, Garas J. Uncontrolled growth of tumour stromal fibroblasts in vitro. Exp Cell Biol 1983;51:201-9.
179. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 1989;20:732-40.
180. Dairkee SH, Blayney C, Smith HS, Hackett AJ. Monoclonal antibody that defines human myoepithelium. Proc Natl Acad Sci U S A 1985;82:7409-13.
181. Dairkee SH, Mayall BH, Smith HS, Hackett AJ. Monoclonal marker that predicts early recurrence of breast cancer. Lancet 1987;1:514.
182. Rosivatz E, Becker I, Specht K, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002;161:1881-91.
183. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005;65: 5996-6000.
184. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415: 530-6.
185. Montel V, Mose ES, Tarin D. Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis. Int J Cancer 2006;119:251-63.
186. Gancberg D, Di LA, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-43.
187. Pfeffer U, Romeo F, Noonan DM, Albini A. Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis 2009;26:547-58.
188. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007;99:147-57.
189. Cohnheim J. Ueber Entzundung und Eiterung. Path Anat Physio Klin Med 1867;40:1-79.
190. Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007;17:3-14.
191. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
192. Cox CV, Martin HM, Kearns PR, et al. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 2007;109:674-82.
193. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-23.
194. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stemcell biology to cancer. Nat Rev Cancer 2003;3:895-902.
195. Bachoo RM, Maher EA, Ligon KL, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002;1:269-77.
196. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007;317:337.
197. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-8.
198. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta 2009;1796:293-308.
199. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-9.
200. Folkman J. Angiogenesis: initiation and modulation. In: Nicholson GL, Milas L, editors. Cancer invasion and metastasis: biologic and therapeutic aspects. New York: Raven Press; 1984, p. 201-9.
201. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235: 442-7.
202. Liotta LA. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986;46:1-7.
203. Takahashi M. An experimental study of metastasis. J Pathol Bacteriol 1915;20:1-13.
204. Coman DR. Decreased mutual adhesiveness, a property of cells from squamous cell carcinomas. Cancer Res 1944;4:625-9.
205. Zeidman I. BUSS JM. Transpulmonary passage of tumor cell emboli. Cancer Res 1952;12:731-3.
206. Lucke B, Breedis C, Woo ZP, Berwick L, Nowell P. Differential growth of metastatic tumors in liver and lung: experiments with rabbit V2 carcinoma. Cancer Res 1952;12:734-8.
207. Klein E. Immediate transformation of solid into ascites tumors;studies on a mammary carcinoma of an inbred mouse strain. Exp Cell Res 1955;8:213-25.
208. Gasic G, Gasic T. Removal of sialic acid from the cell coat in tumor cells and vascular endothelium, and its effects on metastasis. Proc Natl Acad Sci U S A 1962;48:1172-7.
209. 51Cr-labeled tumor cells. Cancer Res 1967;27:412-20.
210. Fisher B, Fisher ER. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 1966; 122:791-8.
211. Giovanella BC, Yim SO, Morgan AC, Stehlin JS, Williams LJ, Jr. Brief communication: metastases of human melanomas transplanted in "nude" mice. J Natl Cancer Inst 1973;50:1051-3.
212. Bross ID, Viadana E, Pickren JW. The metastatic spread of myeloma and leukemias in men. Virchows Arch A Pathol Anat Histol 1975; 365:91-101.
213. Nicolson GL, Winkelhake JL. Organ specificity of blood-borne tumour metastasis determined by cell adhesion? Nature 1975;255: 230-2.
214. Liotta LA, Kleinerman J, Catanzaro P, Rynbrandt D. Degradation of basement membrane by murine tumor cells. J Natl Cancer Inst 1977;58:1427-31.
215. Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-8.
216. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumour growth and metastasis in beige mice. Nature 1980;284: 622-4.
217. Herman EH, Witiak DT, Hellmann K, Waravdekar VS. Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. Adv Pharmacol Chemother 1982;19:249-90.
218. Volk T, Geiger B, Raz A. Motility and adhesive properties of highand low-metastatic murine neoplastic cells. Cancer Res 1984;44: 811-24.
219. Fidler IJ. Macrophages and metastasis-a biological approach to cancer therapy. Cancer Res 1985;45:4714-26.
220. Weiss L, Mayhew E, Rapp DG, Holmes JC. Metastatic inefficiency in mice bearing B16 melanomas. Br J Cancer 1982;45:44-53.
221. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4.
222. 18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990;31:1831-5.
223. Lin WC, Pretlow TP, Pretlow TG, Culp LA. Bacterial lacZ gene as a highly sensitive marker to detect micrometastasis formation during tumor progression. Cancer Res 1990;50:2808-17.
224. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
225. Opdenakker G, Van DJ. Chemotactic factors, passive invasion and metastasis of cancer cells. Immunol Today 1992;13:463-4.
226. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
227. Chishima T, Miyagi Y, Wang X, et al. Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 1997;57:2042-7.
228. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
229. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
230. Bernards R, Weinberg RA. A progression puzzle. Nature 2002; 418:823.
231. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-9.
232. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36[Suppl 1]:59-72. (Pubitemid 37521844)
233. Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer 2006;6:141-6.
234. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449:682-8.
235. Worley LA, Long MD, Onken MD, Harbour JW. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res 2008;18:184-90.
236. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451:147-52.